Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)


Bonaca M. P. , Nault P., Giugliano R. P. , Keech A. C. , Pineda A. L. , Kanevsky E., ...More

CIRCULATION, vol.137, no.4, pp.338-350, 2018 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 137 Issue: 4
  • Publication Date: 2018
  • Doi Number: 10.1161/circulationaha.117.032235
  • Title of Journal : CIRCULATION
  • Page Numbers: pp.338-350

Abstract

Background: The PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor evolocumab reduced low-density lipoprotein cholesterol and cardiovascular events in the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). We investigated the efficacy and safety of evolocumab in patients with peripheral artery disease (PAD) as well as the effect on major adverse limb events.